Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Brookfield Renewable Q3 net loss attributable to unitholders more than doubles to USD 314 million

Brookfield Renewable Q3 net loss attributable to unitholders more than doubles to USD 314 million

BitgetBitget2026/11/04 11:57
  • Brookfield Renewable Partners’ third-quarter non-IFRS funds from operations rose 15% year-over-year to USD 346 million, benefiting from asset recycling and development.
  • The business completed its Boralex acquisition during the quarter and closed its Aypa battery-storage acquisition subsequent to quarter-end.
  • New capacity delivered totaled approximately 2,500 megawatts during the quarter, bringing year-to-date completions to approximately 5,600 megawatts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Renewable Partners LP published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040655PRIMZONEFULLFEED9869959) on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss